Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Shareholder Meeting (November 2025)
29 slides from Genetic Signatures's shareholder meeting presentation, Nov 17, 2025
Slide 1: 2025 Annual General Meeting Chair Address and Presentation
ASX Announcement 17 November 2025 2025 Annual General Meeting Chair Address and Presentation Genetic Signatures Limited [ASX:GSS] (“GSS” or the “Company”) advises in accordance with ASX Listing Rule 3.13.3, a copy of the address by Chair, Caroline Waldron and slides to be presented at today’s Annual
Slide 2: Chair's Address
Chair’s Address Good morning Shareholders, Ladies and Gentlemen. It is a pleasure to welcome you to the 2025 Annual General Meeting of Genetic Signatures Limited. This past financial year, FY2025, has been a year of significant transformation for the Company. This has necessitated courageous decisio
Slide 3: Chair's Address (continued)
In the U.S. market, although the uptake of our EasyScreen™ Gastrointestinal Parasite Detection Kit is progressing slower than initially anticipated, we are optimistic about its long-term prospects. We have adjusted our go-to-market approach and realigned our resources to better position ourselves to
Slide 4: 2025 Annual General Meeting
2025 Annual General Meeting 17 November 2025 2025 Annual General Meeting 17 November 2025 29 November 2023 1
Slide 5: Agenda
2025 Annual General Meeting AGENDA 1. Chair Address 2. CEO Presentation 3. Q&A / Voting Procedure Overview 4. Formal Business of the Meeting 5. General Questions 2
Slide 6: Chair Address – Caroline Waldron
2025 Annual General Meeting 17 November 2025 2025 Annual General Meeting Chair Address – Caroline Waldron 29 November 2023 3
Slide 7: CEO Presentation – Allison Rossiter
2025 Annual General Meeting 17 November 2025 2025 Annual General Meeting CEO Presentation – Allison Rossiter 29 November 2023 4
Slide 8: Patient Case Study – misdiagnosed Giardia
2025 Annual General Meeting Patient Case Study – misdiagnosed Giardia 17 November 2025 Watch Online → “I would have loved access to a Watch Online → PCR test like this”
Slide 9: Blackpool Case Study – Easyscreen Implementation
2025 Annual General Meeting Blackpool Case Study – Easyscreen Implementation 17 November 2025 Challenge: Gastroenteritis diagnosis was slow, fragmented, and often inconclusive. Solution: Adopted EasyScreen Pan-Enteric Detection Kit for all inpatient and community stool samples. Results: • Rapid Resu
Slide 10: Who we are and what we do
2025 Annual General Meeting Who we are and what we do 17 November 2025 Who We Are Genetic Signatures is an Australian ASX-listed molecular diagnostics company, specialising in high-throughput syndromic PCR testing for detecting infectious diseases, helping to diagnose earlier, keeping people healthi
Slide 11: What is 3base® technology
What is 3base® technology 2025 Annual General Meeting 17 November 2025 DNA carries a genetic code consisting of 4 chemical bases. C T G G 3base® is the chemical conversion of cytosine (C) bases into thymine (T) resulting in the T T A A conversion of a native 4-base sequence into a 3-base sequence. G
Slide 12: 2025 - A year of transition
2025 Annual General Meeting 2025 - A year of transition 17 November 2025 On market Appointment of new Appointment of Anne Lockwood & Jenny portfolio review CEO, Allison Rossiter Harry as Non-Executive Directors JULY AUGUST SEPTEMBER OCTOBER 2024 • New Instrument Appointment of ANZ Transition of Chai
Slide 13: Approved products in key markets
Approved products in key markets 2025 Annual General Meeting 17 November 2025 Respiratory Viral Bacterial Enteric Viral Bacterial Parasite 10
Slide 14: Progress in key markets in FY25
Progress in key markets in FY25 2025 Annual General Meeting 17 November 2025 • FY25 revenue increased 66% to • FY25 EMEA revenue up 40% to • Expanded go-to-market strategy, $14.4m, delivering standout year $1.5m fueled by surging demand for engaging stakeholders – from on year growth enteric product
Slide 15: New Strategic Direction – Automation Solution
2025 Annual General Meeting New Strategic Direction – Automation Solution 17 November 2025 Faster development timelines Lower development costs Enhanced automation A Well-Considered Strategic Pivot Fresh Market Assessments • Secures the most commercially viable path • Identified priority syndromic f
Slide 16: Focus on delivering results in FY26
2025 Annual General Meeting Focus on delivering results in FY26 17 November 2025 • Q1 FY26 sales of $5.4 million, representing an increase of 20%, over the previous quarter and a 15% uplift compared to the prior corresponding period; • Quarterly revenue result is the highest since COVID years; • Rev
Slide 17: Strategic priorities for FY26
Strategic priorities for FY26 2025 Annual General Meeting 17 November 2025 Unlock UK Opportunities Expanded Go-To-Market Strategy Building for the Future Engage NHS leaders to prioritise Concentrate commercial efforts on four Development of new automated infection control and outbreak high-priority
Slide 18: Formal Business of the Meeting
Formal Business of the Meeting 15
Slide 19: Q&A / Voting Procedure Overview
Q&A / Voting Procedure Overview 16 16
Slide 20: Consideration of Reports
2025 Annual General Meeting 17 November 2025 Consideration of Reports “To receive and consider the Financial Report, the Directors’ Report and the Independent Auditor’s Report of the Company for the financial year ended 30 June 2025 (Report).” No resolution is required for this item. Following consi
Slide 21: Resolution 1 – Re-election of Director – Dr Neil Gunn
2025 Annual General Meeting 17 November 2025 Resolution 1 – Re-election of Director – Dr Neil Gunn To consider and, if thought fit, pass the following as an ordinary resolution: “That, Dr Neil Gunn who retires in accordance with clause 6.7 of the Company’s Constitution, having offered himself for el
Slide 22: Resolution 2 – Re-election of Director – Ms Caroline Waldron
2025 Annual General Meeting 17 November 2025 Resolution 2 – Re-election of Director – Ms Caroline Waldron To consider and, if thought fit, pass the following as an ordinary resolution: “That, Ms Caroline Waldron who retires in accordance with clause 6.7 of the Company’s Constitution, having offered
Slide 23: Resolution 3 – Adoption of the Remuneration Report
2025 Annual General Meeting 17 November 2025 Resolution 3 – Adoption of the Remuneration Report To consider and, if thought fit, pass the following as an ordinary resolution: “That, the Company’s Remuneration Report for the financial year ended 30 June 2025, as set out in the Directors’ Report, is a
Slide 24: Resolution 4 – Approval to Grant Restricted Rights to Ms Anne Lockwood
2025 Annual General Meeting 17 November 2025 Resolution 4 – Approval to Grant Restricted Rights to a Director, Ms Anne Lockwood To consider and, if thought fit, pass the following as an ordinary resolution: “That, for the purposes of ASX Listing Rule 10.14, and for all other purposes, the issue of 2
Slide 25: Resolution 5 – Approval to Grant Restricted Rights to Dr Jenny Harry
2025 Annual General Meeting 17 November 2025 Resolution 5 – Approval to Grant Restricted Rights to a Director, Dr Jenny Harry To consider and, if thought fit, pass the following as an ordinary resolution: “That, for the purposes of ASX Listing Rule 10.14, and for all other purposes, the issue of 250
Slide 26: General Questions
nosti ics General Questions 23
Slide 27: Thank you for your attendance
Thank you for your attendance 24
Slide 28: Contact Us
Contact Us Allison Rossiter Chief Executive Officer E: allison.rossiter@geneticsignatures.com P: +61 (02) 9870 7580 Karl Pechmann Chief Financial & Operating Officer & Joint Company Secretary E: karl.pechmann@geneticsignatures.com Visit us www.geneticsignatures.com Follow us 25 25
Slide 29: Disclaimer
2025 Annual General Meeting Disclaimer 17 November 2025 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It provides general background information about the Company’s activities current as at t
Genetic Signatures — Shareholder Meeting (November 2025) on 6ix